Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Con | ARNA Message Board Posts

Arena Pharmaceuticals, Inc.

  ARNA website

ARNA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  70 of 77  at  9/26/2019 8:37:02 AM  by

Chazchem


Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

8:30 AM ET, 09/26/2019 - PR Newswire

SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated and inflammatory conditions, including the ongoing ELEVATE UC Phase 3 trial that was initiated this year. These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey.

"Steady-state etrasimod trough concentrations were achieved and maintained from weeks 1 to 12 in patients with moderately to severely active ulcerative colitis treated with 1 or 2 mg etrasimod once-daily. Statistically significant exposure-response relationships favoring 2 mg dosing were demonstrated, with reductions from baseline in circulating lymphocyte count and improvements in modified Mayo Clinic Score," stated Dr. Preston Klassen, Executive Vice President, Head of Research & Development at Arena. "In addition to previously reported dose-response data from OASIS, these new findings further strengthen the etrasimod 2 mg dosing regimen chosen for our Phase 3 ELEVATE UC program."

Presentation Details: Title:Steady-State Trough Concentrations and Their Relationship to Selected Demographic and Clinical Response Measures in Etrasimod-Treated Patients With Moderately-to-Severely Active Ulcerative Colitis

These data will be encored at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) 2019 Annual Meeting, and the American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Meeting.

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 7     Views: 178
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...